Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.


Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients
Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program
4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program
European Society of Cardiology recommends (rivaroxaban) XARELTO® 2.5 mg plus acetylsalicylic acid for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes
Bayer completes sale of iconic Coppertone™ brand to Beiersdorf
Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion